End-of-year letter from the CEO
As the year 2021 is approaching its end it is time to reflect upon key achievements and progress during the year in our work towards our vision for Cereno, the delivery of innovative valuable new therapies for patients with rare and common cardiovascular diseases. This year has been a very progressive year for Cereno with many important milestones achieved. We have continued to expand our pipeline portfolio and made great progress across all three programs. At the same time, we have significantly strengthened our patent protection, secured financing, and established new key collaborations